US HIV Therapeutics Market Analysis Report 2022 to 2030

US HIV Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the US HIV therapeutics market will reach a value of $6.36 Bn from $5.78 Bn in 2022, growing at a CAGR of 1.2% during 2022-2030. The market is primarily dominated by local players such as ViiV Healthcare, Merck & Co, and Bristol-Myers Squibb. The market is driven by innovation in research and development, increasing prevalence, and good governance. The HIV therapeutics market in the US is segmented by type, product, geography, end user, and distribution channel.

ID: IN10USPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: US AUTHOR: Dr. Vishwa Modhia

Buy Now

US HIV Therapeutics Market Analysis Summary

By 2030, it is anticipated that the US HIV therapeutics market will reach a value of $6.36 Bn from $5.78 Bn in 2022, growing at a CAGR of 1.2% during 2022-2030. The approach for HIV therapeutics in the US is Antiretroviral therapy (ART) is the primary treatment for HIV, followed by Post-exposure prophylaxis (PEP), Pre-exposure prophylaxis (PrEP), HIV vaccine, and HIV Cure.

Approximately 1.2 Mn people in the US have HIV. Ending the HIV Epidemic in the US (EHE) is a robust initiative that seeks to accelerate progress in HIV prevention and end the HIV epidemic in the US by 2030. The CDC is working with partners to accelerate progress by delivering key prevention strategies in innovative ways to the populations hardest hit by HIV.

On the basis of medication class, the multi-class combination drugs segment holds the largest market share as it involves the most advanced technology used for the treatment of HIV infection.

US HIV therapeutics market analysis

Market Dynamics

Market Growth Drivers Analysis

In the US, there is an increased uptake of key prevention and treatment strategies for HIV infection. In 2019, nearly 23% of people eligible for pre-exposure prophylaxis (PrEP) were prescribed it, compared to just 5% in 2015.

In the US, HIV medical care was provided to 82% of people with HIV diagnosed in a given year for their HIV infection within one month of diagnosis. This growth in diagnosis and treatment is a market driver for the US HIV therapeutics market. The US federal discretionary funding for HIV/AIDS was $7.4 Bn in 2022

Market Restraints

The research and development high cost for HIV therapeutics may refrain new companies from entering the market. Some HIV/AIDS drugs can cause severe side effects, which can make it difficult for some people to take them. There is still a significant amount of stigma surrounding HIV/AIDS, which can make it difficult for people to get the care and treatment they need.

Competitive Landscape

Key Players

Gilead Sciences (USA)
ViiV Healthcare (USA)
Merck & Co (USA)
Bristol-Myers Squibb (USA)
AbbVie (USA)
Johnson & Johnson (USA)
Novartis
GlaxoSmithKline
Pfizer

Notable Recent Deals

January 2023: In the third quarter, Kornitzer Capital Management increased its holdings in Gilead Sciences shares by 0.5%, according to the company's most recent Securities and Exchange Commission filing. Gilead Sciences, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States. For the treatment of HIV/AIDS, the business offers the drugs Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla.

December 2022: The US Business Action to End HIV, a new coalition of corporations committed to accelerating progress to end HIV in the US by 2030, has been officially launched by the Health Action Alliance and ViiV Healthcare. The coalition's founding members include Ada Health, Avita, BLK, Chispa, CVS Health, Gilead Sciences, Healthvana, National LGBT Chamber of Commerce, OraSure Technologies, The Powell Companies Real, Tinder, Uber, ViiV Healthcare, Walgreens, and Walmart.

Regulations and Reimbursement

The Food and Drug Administration has instituted several proactive measures to expedite the review of treatments, diagnostics, and vaccines for AIDS and related conditions. The Office of the US Global AIDS Coordinator and Global Health Diplomacy leads, manages, and oversees the US President’s Emergency Plan for AIDS Relief (PEPFAR).

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

US HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.